Chronic myelogenous leukemia (CML) is usually diagnosed in the chronic phase. Untreated chronic phase CML will eventually progress to advanced phase (accelerated or blast phase) CML. Tyrosine kinase inhibitors (TKIs) have been shown to induce favorable response rates in patients with accelerated and blast phase CML. The addition of TKIs to chemotherapy has also been associated with improved outcomes in patients with blast phase CML. Allogeneic hematopoietic stem cell transplant remains a potentially curative option for patients with advanced phase CML, although treatment with a course of TKIs will be beneficial as a bridge to transplant. This manuscript discusses the recommendations outlined in the NCCN Guidelines for the diagnosis and management of patients with advanced phase CML.

  • 1.

    HowladerNNooneAM eds. SEER Cancer Statistics Review 1975-2008National Cancer Institute. Bethesda, MDwww.seer.cancer.gov/csr/1975_2008/based on November 2010 SEER data submission posted to the SEER website2011.

    • Search Google Scholar
    • Export Citation
  • 2.

    SiegelRMaJZouZJemalA. Cancer statistics, 2014. CA Cancer J Clin2014;64:929.

  • 3.

    FaderlSTalpazMEstrovZ. The biology of chronic myeloid leukemia. N Engl J Med1999;341:164172.

  • 4.

    VermaDKantarjianHMJonesD. Chronic myeloid leukemia (CML) with P190 BCR-ABL: analysis of characteristics, outcomes, and prognostic significance. Blood2009;114:22322235.

    • Search Google Scholar
    • Export Citation
  • 5.

    SawyersCL. Chronic myeloid leukemia. N Engl J Med1999;340:13301340.

  • 6.

    RadichJPDaiHMaoM. Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc Natl Acad Sci U S A2006;103:27942799.

    • Search Google Scholar
    • Export Citation
  • 7.

    JamiesonCHMAillesLEDyllaSJ. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med2004;351:657667.

    • Search Google Scholar
    • Export Citation
  • 8.

    KantarjianHMDeisserothAKurzrockR. Chronic myelogenous leukemia: a concise update. Blood1993;82:691703.

  • 9.

    SavageDGSzydloRMChaseA. Bone marrow transplantation for chronic myeloid leukaemia: the effects of differing criteria for defining chronic phase on probabilities of survival and relapse. Br J Haematol1997;99:3035.

    • Search Google Scholar
    • Export Citation
  • 10.

    SokalJEBaccaraniMRussoDTuraS. Staging and prognosis in chronic myelogenous leukemia. Semin Hematol1988;25:4961.

  • 11.

    TalpazMSilverRTDrukerBJ. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood2002;99:19281937.

    • Search Google Scholar
    • Export Citation
  • 12.

    CortesJETalpazMO’BrienS. Staging of chronic myeloid leukemia in the imatinib era: an evaluation of the World Health Organization proposal. Cancer2006;106:13061315.

    • Search Google Scholar
    • Export Citation
  • 13.

    SwerdlowSHCampoEHarrisNL. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th edition. Lyon, France: IARC; 2008.

  • 14.

    DrukerBJ. Chronic Myelogenous Leukemia. In: DeVitaVTJrLawrenceTSRosenburgSA eds. DeVita Hellman and Rosenberg’s Cancer: Principles and Practice of Oncology. Vol. 2. 8th edition. Philadelphia, PA: Lippincott Williams & Wilkins; 2007:22672304.

    • Search Google Scholar
    • Export Citation
  • 15.

    GuoJQWangJYArlinghausRB. Detection of BCR-ABL proteins in blood cells of benign phase chronic myelogenous leukemia patients. Cancer Res1991;51:30483051.

    • Search Google Scholar
    • Export Citation
  • 16.

    BiernauxCLoosMSelsA. Detection of major bcr-abl gene expression at a very low level in blood cells of some healthy individuals. Blood1995;86:31183122.

    • Search Google Scholar
    • Export Citation
  • 17.

    BoseSDeiningerMGora-TyborJ. The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: biologic significance and implications for the assessment of minimal residual disease. Blood1998;92:33623367.

    • Search Google Scholar
    • Export Citation
  • 18.

    SokalJCoxEBaccaraniM. Prognostic discrimination in “good-risk” chronic granulocytic leukemia. Blood1984;63:789799.

  • 19.

    HasfordJPfirrmannMHehlmannR. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst1998;90:850858.

    • Search Google Scholar
    • Export Citation
  • 20.

    CortesJETalpazMBeranM. Philadelphia chromosome-negative chronic myelogenous leukemia with rearrangement of the breakpoint cluster region. Long-term follow-up results. Cancer1995;75:464470.

    • Search Google Scholar
    • Export Citation
  • 21.

    ErnstTChaseAJScoreJ. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet2010;42:722726.

    • Search Google Scholar
    • Export Citation
  • 22.

    KohlmannAGrossmannVKleinHU. Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1. J Clin Oncol2010;28:38583865.

    • Search Google Scholar
    • Export Citation
  • 23.

    OhSTSimondsEFJonesC. Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms. Blood2010;116:988992.

    • Search Google Scholar
    • Export Citation
  • 24.

    TefferiA. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia2010;24:11281138.

    • Search Google Scholar
    • Export Citation
  • 25.

    MascarenhasJRoperNChaurasiaPHoffmanR. Epigenetic abnormalities in myeloproliferative neoplasms: a target for novel therapeutic strategies. Clin Epigenetics2011;2:197212.

    • Search Google Scholar
    • Export Citation
  • 26.

    StegelmannFBullingerLSchlenkRF. DNMT3A mutations in myeloproliferative neoplasms. Leukemia2011;25:12171219.

  • 27.

    KlampflTGisslingerHHarutyunyanAS. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med2013;369:23792390.

  • 28.

    MaxsonJEGotlibJPollyeaDA. Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML. N Engl J Med2013;368:17811790.

    • Search Google Scholar
    • Export Citation
  • 29.

    MeggendorferMBacherUAlpermannT. SETBP1 mutations occur in 9% of MDS/MPN and in 4% of MPN cases and are strongly associated with atypical CML, monosomy 7, isochromosome i(17)(q10), ASXL1 and CBL mutations. Leukemia2013;27:18521860.

    • Search Google Scholar
    • Export Citation
  • 30.

    CrossNCReiterA. Fibroblast growth factor receptor and platelet-derived growth factor receptor abnormalities in eosinophilic myeloproliferative disorders. Acta Haematol2008;119:199206.

    • Search Google Scholar
    • Export Citation
  • 31.

    KantarjianHMCortesJO’BrienS. Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. Blood2002;99:35473553.

    • Search Google Scholar
    • Export Citation
  • 32.

    KantarjianHMO’BrienSCortesJE. Treatment of Philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate. Clin Cancer Res2002;8:21672176.

    • Search Google Scholar
    • Export Citation
  • 33.

    SawyersCLHochhausAFeldmanE. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood2002;99:35303539.

    • Search Google Scholar
    • Export Citation
  • 34.

    PalandriFCastagnettiFTestoniN. Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up. Haematologica2008;93:17921796.

    • Search Google Scholar
    • Export Citation
  • 35.

    PalandriFCastagnettiFAlimenaG. The long-term durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: the GIMEMA CML Working Party experience after a 7-year follow-up. Haematologica2009;94:205212.

    • Search Google Scholar
    • Export Citation
  • 36.

    SilverRTCortesJWaltzmanR. Sustained durability of responses and improved progression-free and overall survival with imatinib treatment for accelerated phase and blast crisis chronic myeloid leukemia: long-term follow-up of the STI571 0102 and 0109 trials. Haematologica2009;94:743744.

    • Search Google Scholar
    • Export Citation
  • 37.

    ReaDEtienneGNicoliniF. First-line imatinib mesylate in patients with newly diagnosed accelerated phase-chronic myeloid leukemia. Leukemia2012;26:22542259.

    • Search Google Scholar
    • Export Citation
  • 38.

    OhanianMKantarjianHMQuintas-CardamaA. Tyrosine kinase inhibitors as initial therapy for patients with chronic myeloid leukemia in accelerated phase. Clin Lymphoma Myeloma Leuk2014;14:155-162 e151.

    • Search Google Scholar
    • Export Citation
  • 39.

    CortesJKimDWRaffouxE. Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase. Leukemia2008;22:21762183.

    • Search Google Scholar
    • Export Citation
  • 40.

    ApperleyJFCortesJEKimDW. Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START A trial. J Clin Oncol2009;27:34723479.

    • Search Google Scholar
    • Export Citation
  • 41.

    KantarjianHCortesJKimDW. Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up. Blood2009;113:63226329.

    • Search Google Scholar
    • Export Citation
  • 42.

    le CoutrePDGilesFJHochhausA. Nilotinib in patients with Ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results. Leukemia2012;26:11891194.

    • Search Google Scholar
    • Export Citation
  • 43.

    GilesFJKantarjianHMle CoutrePD. Nilotinib is effective in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blastic phase. Leukemia2012;26:959962.

    • Search Google Scholar
    • Export Citation
  • 44.

    Gambacorti-PasseriniCCortesJEKhouryHJ. Safety and efficacy of bosutinib in patients with AP and BP CML and ph+ ALL following resistance/intolerance to imatinib and other TKIs: Update from study SKI-200 [abstract]. J Clin Oncol2010;28(Suppl):Abstract 6509.

    • Search Google Scholar
    • Export Citation
  • 45.

    CortesJEKimDWPinilla-IbarzJ. A Phase 2 Trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med2013;369:17831796.

    • Search Google Scholar
    • Export Citation
  • 46.

    KantarjianHMKimDWPinilla-IbarzJ. Ponatinib (PON) in patients (pts) with Philadelphia chromosome-positive (Ph+) leukemias resistant or intolerant to dasatinib or nilotinib, or with the T315I mutation: longer-term follow up of the PACE trial [abstract]. J Clin Oncol2014;32(Suppl):Abstract 7081.

    • Search Google Scholar
    • Export Citation
  • 47.

    GuilhotFApperleyJKimDW. Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. Blood2007;109:41434150.

    • Search Google Scholar
    • Export Citation
  • 48.

    CortesJRousselotPKimDW. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood2007;109:32073213.

    • Search Google Scholar
    • Export Citation
  • 49.

    SaglioGHochhausAGohYT. Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study: efficacy and tolerability of 140 milligrams once daily and 70 milligrams twice daily. Cancer2010;116:38523861.

    • Search Google Scholar
    • Export Citation
  • 50.

    le CoutrePOttmannOGGilesF. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia. Blood2008;111:18341839.

    • Search Google Scholar
    • Export Citation
  • 51.

    EfficaceFBaccaraniMBrecciaM. Chronic fatigue is the most important factor limiting health-related quality of life of chronic myeloid leukemia patients treated with imatinib. Leukemia2013;27:15111519.

    • Search Google Scholar
    • Export Citation
  • 52.

    BermanENicolaidesMMakiRG. Altered bone and mineral metabolism in patients receiving imatinib mesylate. N Engl J Med2006;354:20062013.

    • Search Google Scholar
    • Export Citation
  • 53.

    BermanEGirotraMChengC. Effect of long term imatinib on bone in adults with chronic myelogenous leukemia and gastrointestinal stromal tumors. Leuk Res2013;37:790794.

    • Search Google Scholar
    • Export Citation
  • 54.

    Quintas-CardamaAKantarjianHO’BrienS. Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol2007;25:39083914.

    • Search Google Scholar
    • Export Citation
  • 55.

    PorkkaKKhouryHJPaquetteRL. Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion. Cancer2010;116:377386.

    • Search Google Scholar
    • Export Citation
  • 56.

    MatteiDFeolaMOrzanF. Reversible dasatinib-induced pulmonary arterial hypertension and right ventricle failure in a previously allografted CML patient. Bone Marrow Transplant2009;43:967968.

    • Search Google Scholar
    • Export Citation
  • 57.

    RasheedWFlaimBSeymourJF. Reversible severe pulmonary hypertension secondary to dasatinib in a patient with chronic myeloid leukemia. Leuk Res2009;33:861864.

    • Search Google Scholar
    • Export Citation
  • 58.

    DumitrescuDSeckCten FreyhausH. Fully reversible pulmonary arterial hypertension associated with dasatinib treatment for chronic myeloid leukaemia. Eur Respir J2011;38:218220.

    • Search Google Scholar
    • Export Citation
  • 59.

    HennigsJKKellerGBaumannHJ. Multi tyrosine kinase inhibitor dasatinib as novel cause of severe pre-capillary pulmonary hypertension?BMC Pulm Med2011;11:30.

    • Search Google Scholar
    • Export Citation
  • 60.

    MontaniDBergotEGuntherS. Pulmonary arterial hypertension in patients treated by dasatinib. Circulation2012;125:21282137.

  • 61.

    OrlandiEMRoccaBPazzanoASGhioS. Reversible pulmonary arterial hypertension likely related to long-term, low-dose dasatinib treatment for chronic myeloid leukaemia. Leuk Res2012;36:e46.

    • Search Google Scholar
    • Export Citation
  • 62.

    AichbergerKJHerndlhoferSSchernthanerGH. Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML. Am J Hematol2011;86:533539.

    • Search Google Scholar
    • Export Citation
  • 63.

    TefferiALetendreL. Nilotinib treatment-associated peripheral artery disease and sudden death: yet another reason to stick to imatinib as front-line therapy for chronic myelogenous leukemia. Am J Hematol2011;86:610611.

    • Search Google Scholar
    • Export Citation
  • 64.

    GilesFJMauroMJHongF. Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis. Leukemia2013;27:13101315.

    • Search Google Scholar
    • Export Citation
  • 65.

    FDA Drug Safety Communication: FDA asks manufacturer of the leukemia drug Iclusig (ponatinib) to suspend marketing and sales. U.S. Food and Drug Administration Web site. Available at: http://www.fda.gov/Drugs/DrugSafety/ucm373040.htm; 2013. Accessed October 21 2014.

    • Search Google Scholar
    • Export Citation
  • 66.

    Ponatinib [package insert]. Cambridge, MA: ARIAD Pharmaceuticals, Inc.; 2014.

  • 67.

    AliROzkalemkasFKimyaY. Imatinib use during pregnancy and breast feeding: a case report and review of the literature. Arch Gynecol Obstet2009;280:169175.

    • Search Google Scholar
    • Export Citation
  • 68.

    AlKindiSDennisonDPathareA. Imatinib in pregnancy. Eur J Haematol2005;74:535537.

  • 69.

    AultPKantarjianHO’BrienS. Pregnancy among patients with chronic myeloid leukemia treated with imatinib. J Clin Oncol2006;24:12041208.

    • Search Google Scholar
    • Export Citation
  • 70.

    ChoudharyDRMishraPKumarR. Pregnancy on imatinib: fatal outcome with meningocele. Ann Oncol2006;17:178179.

  • 71.

    HeartinEWalkinshawSClarkRE. Successful outcome of pregnancy in chronic myeloid leukaemia treated with imatinib. Leuk Lymphoma2004;45:13071308.

    • Search Google Scholar
    • Export Citation
  • 72.

    PrabhashKSastryPSBiswasG. Pregnancy outcome of two patients treated with imatinib. Ann Oncol2005;16:19831984.

  • 73.

    PyeSMCortesJAultP. The effects of imatinib on pregnancy outcome. Blood2008;111:55055508.

  • 74.

    RamasamyKHaydenJLimZ. Successful pregnancies involving men with chronic myeloid leukaemia on imatinib therapy. Br J Haematol2007;137:374375.

    • Search Google Scholar
    • Export Citation
  • 75.

    CortesJO’BrienSAultP. Pregnancy outcomes among patients with chronic myeloid leukemia treated with dasatinib [abstract]. Blood2008;112:Abstract 3230.

    • Search Google Scholar
    • Export Citation
  • 76.

    ConchonMSanabaniSSSerpaM. Successful pregnancy and delivery in a patient with chronic myeloid leukemia while on dasatinib therapy. Adv Hematol2010;2010:136252136252.

    • Search Google Scholar
    • Export Citation
  • 77.

    OweiniHOtrockZKMahfouzRABazarbachiA. Successful pregnancy involving a man with chronic myeloid leukemia on dasatinib. Arch Gynecol Obstet2011;283:133134.

    • Search Google Scholar
    • Export Citation
  • 78.

    ConchonMSanabaniSSBenditI. Two successful pregnancies in a woman with chronic myeloid leukemia exposed to nilotinib during the first trimester of her second pregnancy: case study. J Hematol Oncol2009;2:4242.

    • Search Google Scholar
    • Export Citation
  • 79.

    KantarjianHMTalpazMKontoyiannisD. Treatment of chronic myelogenous leukemia in accelerated and blastic phases with daunorubicin, high-dose cytarabine, and granulocyte-macrophage colony-stimulating factor. J Clin Oncol1992;10:398405.

    • Search Google Scholar
    • Export Citation
  • 80.

    DerderianPMKantarjianHMTalpazM. Chronic myelogenous leukemia in the lymphoid blastic phase: characteristics, treatment response, and prognosis. Am J Med1993;94:6974.

    • Search Google Scholar
    • Export Citation
  • 81.

    DannEJAnastasiJLarsonRA. High-dose cladribine therapy for chronic myelogenous leukemia in the accelerated or blast phase. J Clin Oncol1998;16:14981504.

    • Search Google Scholar
    • Export Citation
  • 82.

    SacchiSKantarjianHMO’BrienS. Chronic myelogenous leukemia in nonlymphoid blastic phase: analysis of the results of first salvage therapy with three different treatment approaches for 162 patients. Cancer1999;86:26322641.

    • Search Google Scholar
    • Export Citation
  • 83.

    AxdorphUStenkeLGrimforsG. Intensive chemotherapy in patients with chronic myelogenous leukaemia (CML) in accelerated or blastic phase--a report from the Swedish CML Group. Br J Haematol2002;118:10481054.

    • Search Google Scholar
    • Export Citation
  • 84.

    ThomasDAFaderlSCortesJ. Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood2004;103:43964407.

    • Search Google Scholar
    • Export Citation
  • 85.

    YanadaMTakeuchiJSugiuraI. High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group. J Clin Oncol2006;24:460466.

    • Search Google Scholar
    • Export Citation
  • 86.

    de LabartheARousselotPHuguet-RigalF. Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study. Blood2007;109:14081413.

    • Search Google Scholar
    • Export Citation
  • 87.

    OkiYKantarjianHMGharibyanV. Phase II study of low-dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia. Cancer2007;109:899906.

    • Search Google Scholar
    • Export Citation
  • 88.

    Quintas-CardamaAKantarjianHGarcia-ManeroG. A pilot study of imatinib, low-dose cytarabine and idarubicin for patients with chronic myeloid leukemia in myeloid blast phase. Leuk Lymphoma2007;48:283289.

    • Search Google Scholar
    • Export Citation
  • 89.

    FruehaufSTopalyJBussEC. Imatinib combined with mitoxantrone/etoposide and cytarabine is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisis. Cancer2007;109:15431549.

    • Search Google Scholar
    • Export Citation
  • 90.

    ThomasDAO’BrienSMFaderlS. Long-term outcome after hyper-CVAD and imatinib (IM) for de novo or minimally treated Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph-ALL) [abstract]. J Clin Oncol2010;28(Suppl):Abstract 6506.

    • Search Google Scholar
    • Export Citation
  • 91.

    DeauBNicoliniFEGuilhotJ. The addition of daunorubicin to imatinib mesylate in combination with cytarabine improves the response rate and the survival of patients with myeloid blast crisis chronic myelogenous leukemia (AFR01 study). Leuk Res2011;35:777782.

    • Search Google Scholar
    • Export Citation
  • 92.

    JabbourEKantarjianHMThomasDA. Phase II study of combination of hyperCVAD with ponatinib in frontline therapy of patients (pts) with Philadelphia chromosome (Ph) positive acute lymphoblastic leukemia (ALL) [abstract]. J Clin Oncol2013;31(Suppl):Abstract 7024.

    • Search Google Scholar
    • Export Citation
  • 93.

    BenjaminiODumlaoTLKantarjianH. Phase II trial of hyper CVAD and dasatinib in patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia or blast phase chronic myeloid leukemia. Am J Hematol2014;89:282287.

    • Search Google Scholar
    • Export Citation
  • 94.

    StratiPKantarjianHThomasD. HCVAD plus imatinib or dasatinib in lymphoid blastic phase chronic myeloid leukemia. Cancer2014;120:373380.

    • Search Google Scholar
    • Export Citation
  • 95.

    NicoliniFEKhouryHJAkardL. Omacetaxine mepesuccinate for patients with accelerated phase chronic myeloid leukemia with resistance or intolerance to two or more tyrosine kinase inhibitors. Haematologica2013;98:e7879.

    • Search Google Scholar
    • Export Citation
  • 96.

    KhouryHJCortesJBaccaraniM. Omacetaxine mepesuccinate in patients with advanced chronic myeloid leukemia with resistance or intolerance to tyrosine kinase inhibitors [published online ahead of print April 28, 2014]. Leuk Lymphoma.

    • Search Google Scholar
    • Export Citation
  • 97.

    FavaCKantarjianHMJabbourE. Failure to achieve a complete hematologic response at the time of a major cytogenetic response with second-generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blast phase. Blood2009;113:50585063.

    • Search Google Scholar
    • Export Citation
  • 98.

    BranfordSMeloJVHughesTP. Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter?Blood2009;114:54265435.

    • Search Google Scholar
    • Export Citation
  • 99.

    JabbourEBranfordSSaglioG. Practical advice for determining the role of BCR-ABL mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia. Cancer2011;117:18001811.

    • Search Google Scholar
    • Export Citation
  • 100.

    SoveriniSHochhausANicoliniFE. BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood2011;118:12081215.

    • Search Google Scholar
    • Export Citation
  • 101.

    MullerMCCortesJEKimDW. Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations. Blood2009;114:49444953.

    • Search Google Scholar
    • Export Citation
  • 102.

    HughesTSaglioGBranfordS. Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase. J Clin Oncol2009;27:42044210.

    • Search Google Scholar
    • Export Citation
  • 103.

    KhouryHJCortesJEKantarjianHM. Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure. Blood2012;119:34033412.

    • Search Google Scholar
    • Export Citation
  • 104.

    HochhausAKimDWPinilla-IbarzJ. Molecular responses with ponatinib in patients with philadelphia chromosome positive (ph+) leukemia: results from the PACE trial [abstract]. Blood2012;120:Abstract 3763.

    • Search Google Scholar
    • Export Citation
  • 105.

    ShahNPCortesJEKimDW. Impact of baseline (BL) mutations, including low-level and compound mutations, on ponatinib response and end of treatment (EOT) mutation analysis in patients (pts) with chronic phase chronic myeloid leukemia (CP-CML) [abstract]. Blood2013;122:Abstract 652.

    • Search Google Scholar
    • Export Citation
  • 106.

    RadichJ. Stem cell transplant for chronic myeloid leukemia in the imatinib era. Semin Hematol2010;47:354361.

  • 107.

    PavluJSzydloRMGoldmanJMApperleyJF. Three decades of transplantation for chronic myeloid leukemia: what have we learned?Blood2011;117:755763.

    • Search Google Scholar
    • Export Citation
  • 108.

    DaviesSMDeForTEMcGlavePB. Equivalent outcomes in patients with chronic myelogenous leukemia after early transplantation of phenotypically matched bone marrow from related or unrelated donors. Am J Med2001;110:339346.

    • Search Google Scholar
    • Export Citation
  • 109.

    HansenJAGooleyTAMartinPJ. Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. N Engl J Med1998;338:962968.

    • Search Google Scholar
    • Export Citation
  • 110.

    HorowitzMMRowlingsPAPasswegJR. Allogeneic bone marrow transplantation for CML: a report from the International Bone Marrow Transplant Registry. Bone Marrow Transplant1996;17(Suppl 3):S56.

    • Search Google Scholar
    • Export Citation
  • 111.

    CrawleyCSzydloRLalancetteM. Outcomes of reduced-intensity transplantation for chronic myeloid leukemia: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT. Blood2005;106:29692976.

    • Search Google Scholar
    • Export Citation
  • 112.

    McSweeneyPANiederwieserDShizuruJA. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood2001;97:33903400.

    • Search Google Scholar
    • Export Citation
  • 113.

    OrRShapiraMYResnickI. Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase. Blood2003;101:441445.

    • Search Google Scholar
    • Export Citation
  • 114.

    FaberEKozaVVitekA. Reduced-intensity conditioning for allogeneic stem cell transplantation in patients with chronic myeloid leukemia is associated with better overall survival but inferior disease-free survival when compared with myeloablative conditioning - a retrospective study of the Czech National Hematopoietic Stem Cell Transplantation Registry. Neoplasma2007;54:443446.

    • Search Google Scholar
    • Export Citation
  • 115.

    KebriaeiPDetryMAGiraltS. Long-term follow-up of allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning for patients with chronic myeloid leukemia. Blood2007;110:34563462.

    • Search Google Scholar
    • Export Citation
  • 116.

    PoireXArtzALarsonRA. Allogeneic stem cell transplantation with alemtuzumab-based conditioning for patients with advanced chronic myelogenous leukemia. Leuk Lymphoma2009;50:8591.

    • Search Google Scholar
    • Export Citation
  • 117.

    WarlickEAhnKWPedersenTL. Reduced intensity conditioning is superior to nonmyeloablative conditioning for older chronic myelogenous leukemia patients undergoing hematopoietic cell transplant during the tyrosine kinase inhibitor era. Blood2012;119:40834090.

    • Search Google Scholar
    • Export Citation
  • 118.

    WeisserMSchleuningMHaferlachC. Allogeneic stem-cell transplantation provides excellent results in advanced stage chronic myeloid leukemia with major cytogenetic response to pre-transplant imatinib therapy. Leuk Lymphoma2007;48:295301.

    • Search Google Scholar
    • Export Citation
  • 119.

    BaccaraniMCortesJPaneF. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol2009;27:60416051.

    • Search Google Scholar
    • Export Citation
  • 120.

    VelevNCortesJChamplinR. Stem cell transplantation for patients with chronic myeloid leukemia resistant to tyrosine kinase inhibitors with BCR-ABL kinase domain mutation T315I. Cancer2010;116:36313637.

    • Search Google Scholar
    • Export Citation
  • 121.

    JabbourECortesJSantosFP. Results of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia patients who failed tyrosine kinase inhibitors after developing BCR-ABL1 kinase domain mutations. Blood2011;117:36413647.

    • Search Google Scholar
    • Export Citation
  • 122.

    NicoliniFEBasakGWSoveriniS. Allogeneic stem cell transplantation for patients harboring T315I BCR-ABL mutated leukemias. Blood2011;118:56975700.

    • Search Google Scholar
    • Export Citation
  • 123.

    RothMAntinJAshR. Prognostic significance of Philadelphia chromosome-positive cells detected by the polymerase chain reaction after allogeneic bone marrow transplant for chronic myelogenous leukemia. Blood1992;79:276282.

    • Search Google Scholar
    • Export Citation
  • 124.

    DelageRSoifferRDearKRitzJ. Clinical significance of bcr-abl gene rearrangement detected by polymerase chain reaction after allogeneic bone marrow transplantation in chronic myelogenous leukemia. Blood1991;78:27592767.

    • Search Google Scholar
    • Export Citation
  • 125.

    RadichJPGehlyGGooleyT. Polymerase chain reaction detection of the BCR-ABL fusion transcript after allogeneic marrow transplantation for chronic myeloid leukemia: results and implications in 346 patients. Blood1995;85:26322638.

    • Search Google Scholar
    • Export Citation
  • 126.

    MackinnonSBarnettLHellerG. Polymerase chain reaction is highly predictive of relapse in patients following T cell-depleted allogeneic bone marrow transplantation for chronic myeloid leukemia. Bone Marrow Transplant1996;17:643647.

    • Search Google Scholar
    • Export Citation
  • 127.

    OlavarriaEKanferESzydloR. Early detection of BCR-ABL transcripts by quantitative reverse transcriptase-polymerase chain reaction predicts outcome after allogeneic stem cell transplantation for chronic myeloid leukemia. Blood2001;97:15601565.

    • Search Google Scholar
    • Export Citation
  • 128.

    RadichJPGooleyTBryantE. The significance of bcr-abl molecular detection in chronic myeloid leukemia patients “late,” 18 months or more after transplantation. Blood2001;98:17011707.

    • Search Google Scholar
    • Export Citation
  • 129.

    CostelloRTKirkJGabertJ. Value of PCR analysis for long term survivors after allogeneic bone marrow transplant for chronic myelogenous leukemia: a comparative study. Leuk Lymphoma1996;20:239243.

    • Search Google Scholar
    • Export Citation
  • 130.

    van RheeFLinFCrossNC. Detection of residual leukaemia more than 10 years after allogeneic bone marrow transplantation for chronic myelogenous leukaemia. Bone Marrow Transplant1994;14:609612.

    • Search Google Scholar
    • Export Citation
  • 131.

    KolbHJSchattenbergAGoldmanJM. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood1995;86:20412050.

    • Search Google Scholar
    • Export Citation
  • 132.

    DazziFSzydloRMCrossNC. Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Blood2000;96:27122716.

    • Search Google Scholar
    • Export Citation
  • 133.

    LuznikLFuchsEJ. Donor lymphocyte infusions to treat hematologic malignancies in relapse after allogeneic blood or marrow transplantation. Cancer Control2002;9:123137.

    • Search Google Scholar
    • Export Citation
  • 134.

    MichalletASNicoliniFFurstS. Outcome and long-term follow-up of alloreactive donor lymphocyte infusions given for relapse after myeloablative allogeneic hematopoietic stem cell transplantations (HSCT). Bone Marrow Transplant2005;35:601608.

    • Search Google Scholar
    • Export Citation
  • 135.

    DazziFSzydloRMCraddockC. Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia. Blood2000;95:6771.

    • Search Google Scholar
    • Export Citation
  • 136.

    ShimoniAGajewskiJADonatoM. Long-Term follow-up of recipients of CD8-depleted donor lymphocyte infusions for the treatment of chronic myelogenous leukemia relapsing after allogeneic progenitor cell transplantation. Biol Blood Marrow Transplant2001;7:568575.

    • Search Google Scholar
    • Export Citation
  • 137.

    GilleeceMHDazziF. Donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukaemia. Leuk Lymphoma2003;44:2328.

    • Search Google Scholar
    • Export Citation
  • 138.

    PosthumaEFMarijtEWBargeRM. Alpha-interferon with very-low-dose donor lymphocyte infusion for hematologic or cytogenetic relapse of chronic myeloid leukemia induces rapid and durable complete remissions and is associated with acceptable graft-versus-host disease. Biol Blood Marrow Transplant2004;10:204212.

    • Search Google Scholar
    • Export Citation
  • 139.

    SimulaMPMarktelSFozzaC. Response to donor lymphocyte infusions for chronic myeloid leukemia is dose-dependent: the importance of escalating the cell dose to maximize therapeutic efficacy. Leukemia2007;21:943948.

    • Search Google Scholar
    • Export Citation
  • 140.

    KantarjianHMO’BrienSCortesJE. Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia. Blood2002;100:15901595.

    • Search Google Scholar
    • Export Citation
  • 141.

    OlavarriaEOttmannOGDeiningerM. Response to imatinib in patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Leukemia2003;17:17071712.

    • Search Google Scholar
    • Export Citation
  • 142.

    AnderliniPShethSHicksK. Re: Imatinib mesylate administration in the first 100 days after stem cell transplantation. Biol Blood Marrow Transplant2004;10:883884.

    • Search Google Scholar
    • Export Citation
  • 143.

    DeAngeloDJHochbergEPAlyeaEP. Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease. Clin Cancer Res2004;10:50655071.

    • Search Google Scholar
    • Export Citation
  • 144.

    PalandriFAmabileMRostiG. Imatinib therapy for chronic myeloid leukemia patients who relapse after allogeneic stem cell transplantation: a molecular analysis. Bone Marrow Transplant2007;39:189191.

    • Search Google Scholar
    • Export Citation
  • 145.

    ConchonMSanabaniSSBenditI. The use of imatinib mesylate as a lifesaving treatment of chronic myeloid leukemia relapse after bone marrow transplantation. J Transplant2009;2009:357093.

    • Search Google Scholar
    • Export Citation
  • 146.

    HessGBunjesDSiegertW. Sustained complete molecular remissions after treatment with imatinib-mesylate in patients with failure after allogeneic stem cell transplantation for chronic myelogenous leukemia: results of a prospective phase II open-label multicenter study. J Clin Oncol2005;23:75837593.

    • Search Google Scholar
    • Export Citation
  • 147.

    WrightMPShepherdJDBarnettMJ. Response to tyrosine kinase inhibitor therapy in patients with chronic myelogenous leukemia relapsing in chronic and advanced phase following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant2010;16:639646.

    • Search Google Scholar
    • Export Citation
  • 148.

    CarpenterPASnyderDSFlowersME. Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia. Blood2007;109:27912793.

    • Search Google Scholar
    • Export Citation
  • 149.

    OlavarriaESiddiqueSGriffithsMJ. Posttransplantation imatinib as a strategy to postpone the requirement for immunotherapy in patients undergoing reduced-intensity allografts for chronic myeloid leukemia. Blood2007;110:46144617.

    • Search Google Scholar
    • Export Citation
  • 150.

    WeisserMTischerJSchnittgerS. A comparison of donor lymphocyte infusions or imatinib mesylate for patients with chronic myelogenous leukemia who have relapsed after allogeneic stem cell transplantation. Haematologica2006;91:663666.

    • Search Google Scholar
    • Export Citation
  • 151.

    SavaniBNMonteroAKurlanderR. Imatinib synergizes with donor lymphocyte infusions to achieve rapid molecular remission of CML relapsing after allogeneic stem cell transplantation. Bone Marrow Transplant2005;36:10091015.

    • Search Google Scholar
    • Export Citation
  • 152.

    AtallahEKantarjianHDe LimaM. The role of dasatinib in patients with philadelphia (Ph) positive acute lymphocytic leukemia (ALL) and chronic myeloid leukemia (CML) relapsing after stem cell transplantation (SCT) [abstract]. Blood2006;108:Abstract 4520.

    • Search Google Scholar
    • Export Citation
  • 153.

    O’ConnorLMLangabeerSMcCannSRConneallyE. Restoration of donor chimerism by nilotinib in a chronic myeloid leukaemia patient post mutation-associated imatinib mesylate resistance and allogeneic stem cell transplant failure. Bone Marrow Transplant2008;42:833835.

    • Search Google Scholar
    • Export Citation
  • 154.

    BrecciaMCannellaLStefanizziC. Efficacy of dasatinib in a chronic myeloid leukemia patient with disease molecular relapse and chronic GVHD after haploidentical BMT: an immunomodulatory effect?Bone Marrow Transplant2009;44:331332.

    • Search Google Scholar
    • Export Citation
  • 155.

    KlyuchnikovESchafhausenPKrogerN. Second-generation tyrosine kinase inhibitors in the post-transplant period in patients with chronic myeloid leukemia or Philadelphia-positive acute lymphoblastic leukemia. Acta Haematol2009;122:610.

    • Search Google Scholar
    • Export Citation
  • 156.

    GarlandPDazziFMarinD. Dasatinib may not suppress the GVL effect of donor lymphocyte infusions for CML. Bone Marrow Transplant2010;45:395396.

    • Search Google Scholar
    • Export Citation
  • 157.

    PorkkaKKoskenvesaPLundanT. Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia. Blood2008;112:10051012.

    • Search Google Scholar
    • Export Citation
  • 158.

    OcheniSIwanskiGBSchafhausenP. Characterisation of extramedullary relapse in patients with chronic myeloid leukemia in advanced disease after allogeneic stem cell transplantation. Leuk Lymphoma2009;50:551558.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 183 182 29
PDF Downloads 45 45 10
EPUB Downloads 0 0 0